Recent Updates
Recently added Catalysts
VCYT Neutral Sentiment Score: 50/100

Veracyte to Participate in Upcoming Investor Conferences

Key Takeaway: Veracyte is set to participate in upcoming investor conferences, indicating its ongoing engagement with the investment community. The article does not provide specific details about the conferences or the topics to be discussed. This participation may enhance Veracyte's visibility among investors and stakeholders.
Price reaction · baseline $41.5 (2026-05-18 close) · hit after-hours · 3 other VCYT headline(s) in the window, move may be shared
day 0 close · peak
+0.5%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences.
• William Blair 46thAnnual Growth Stock Conference – Chicago, ILPresentation on Tuesday, June 2ndat 2:00 p.m. Central Time
• 2026 Jefferies Global Healthcare Conference – New York, NYFireside chat on Thursday, June 4that 8:10 a.m. Eastern Time
Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website athttp://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care.Veracyte’s Diagnostics Platformcombines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continuedinnovation and pipeline development. The company’s portfolio includes theAfirma® Genomic Sequencing Classifier test,Decipher® Bladder Genomic Classifier test,Decipher® Prostate Genomic Classifier test,Prosigna® Breast Risk of Recurrence test, and theTrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’swebsiteor follow the company onLinkedInorX (Twitter).
Last updated: May 19, 2026